drugset
drugset / Trial / NCT07364513

Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies

NCT07364513 ↗

Phase 1 Recruiting 6 enrolled ImmuneSensor Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

Open-Label Study (Phase Ib) of Type 1 Interferonopathy patients receiving IMSB301 monotherapy.

Timeline

Start
2026-01-12
Primary completion
2026-07-30
Completion
2026-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IMSB301 Unknown — —

Indications

type 1 interferonopathy